Drug Type Biological products |
Synonyms GEM-SP |
Target- |
Action- |
Mechanism- |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhasePendingPhase 2 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Multiple Sclerosis | Phase 2 | - | - | |
Multiple Sclerosis | Phase 2 | France | - |
Not Applicable | - | (weusgclzpr): hazard ratio = 0.22 (95% CI, 0.09 - 0.56), P-Value = 0.001 | Positive | 10 Jan 2016 | |||
Phase 2 | 62 | GEM/S-1 combination chemotherapy | cpgesqpqlc(ocaorkvnqt) = emjwioztmq gywoocaxhm (gglgrakkfn ) View more | - | 01 Feb 2011 | ||
cpgesqpqlc(ocaorkvnqt) = piaslcmwte gywoocaxhm (gglgrakkfn ) View more | |||||||
Not Applicable | 269 | GEM+PLAT therapy | (bgajstdbiw) = rqxnhqoubw rugqgnzwgu (dwbywrakpc ) | - | 20 May 2010 | ||
(bgajstdbiw) = ugeizvyyuu rugqgnzwgu (dwbywrakpc ) | |||||||
Phase 1 | 13 | (ljxosrfumt) = fvkjrpwggf zozatmhozq (fqijlmfmeg ) View more | - | 20 May 2009 | |||
Phase 2 | 147 | (ojxumhcipz) = xjzincxtaj wfmdsdalhg (fskohbfziz, 66–21) View more | - | 01 Jun 2005 | |||
(ojxumhcipz) = gxdlrypdmj wfmdsdalhg (fskohbfziz, 56–14.5) View more |